Technical Analysis for FATE - Fate Therapeutics, Inc.

Grade Last Price % Change Price Change
grade B 10.77 -5.19% -0.59
FATE closed up 2.43 percent on Tuesday, August 14, 2018, on 53 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Flat
See historical FATE trend table...

Date Alert Name Type % Chg
Aug 14 Crossed Above 50 DMA Bullish -5.19%
Aug 14 MACD Bullish Centerline Cross Bullish -5.19%
Aug 14 180 Bullish Setup Bullish Swing Setup -5.19%
Aug 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.19%
Aug 14 NR7 Range Contraction -5.19%
Aug 14 Inside Day Range Contraction -5.19%
Aug 14 Wide Bands Range Expansion -5.19%
Aug 14 Overbought Stochastic Strength -5.19%
Aug 13 Fell Below 50 DMA Bearish -2.89%
Aug 13 Stochastic Sell Signal Bearish -2.89%

Older signals for FATE ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Is FATE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.45
52 Week Low 2.81
Average Volume 614,759
200-Day Moving Average 9.1519
50-Day Moving Average 11.2924
20-Day Moving Average 10.348
10-Day Moving Average 10.822
Average True Range 0.814
ADX 24.33
+DI 24.4991
-DI 14.0301
Chandelier Exit (Long, 3 ATRs ) 9.598
Chandelier Exit (Short, 3 ATRs ) 11.082
Upper Bollinger Band 12.231
Lower Bollinger Band 8.465
Percent B (%b) 0.77
BandWidth 36.393506
MACD Line 0.0319
MACD Signal Line -0.1987
MACD Histogram 0.2305
Fundamentals Value
Market Cap 470.46 Million
Num Shares 41.4 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -11.83
Price-to-Sales 42.87
Price-to-Book 3.19
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.02
Resistance 3 (R3) 11.98 11.72 11.91
Resistance 2 (R2) 11.72 11.55 11.74 11.87
Resistance 1 (R1) 11.54 11.45 11.63 11.58 11.84
Pivot Point 11.28 11.28 11.33 11.30 11.28
Support 1 (S1) 11.10 11.11 11.19 11.14 10.88
Support 2 (S2) 10.84 11.01 10.86 10.85
Support 3 (S3) 10.66 10.84 10.81
Support 4 (S4) 10.70